The multicenter randomized, double-blind, placebo-controlled phase 3 RATIFY trial evaluated the orally available type 1 FLT3i midostaurin combined with IC in younger (age < 60) patients with newly diagnosed (ND) AML and FLT3-ITD and/or TKD mutations [12]. Here, FLT3 is linked to acute myeloid leukemia.